


ASENT 2023 ANNUAL MEETING

March 13-15, 2023

**Virtual Neuroscience and
Neurotherapeutics Conference**



ADVANCE PROGRAM

A Quick Look at ASENT 2023

Annual Meeting Overview

ASENT 2023 is the premier neurotherapeutics conference where senior leaders from payers, providers, employers, investors, fast-growing startups, pharma, policymakers, funders and innovation centers in the neurology and neuroscience space gather to ask one question: how can we improve the process of bringing neurotherapeutics to market?

The conference content will focus on the latest science in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy and biomarkers, and of course the latest drug therapies and devices. The event features plenary sessions, panel discussions, networking meetings, outstanding pipeline presentations and poster sessions.

MEETING DETAILS

ASENT 2023 Meeting Dates

Monday, March 13 -

Wednesday, March 15, 2023

VIRTUAL FORMAT: ONLINE

ABSTRACT SUBMISSIONS

<https://bit.ly/abstractsasant2023>

Abstract Submission Deadline

January 23, 2023

REGISTRATION IS OPEN

<https://asent.org/Annual-Meeting>

Annual Meeting Registration Deadline

March 13, 2023

WHO ATTENDS

Clinician-Investigators

Neuroscience Trainees

Neuroscientist Researchers

Industry Research Scientists

Clinicians

Advocacy Group Leaders

Chief Medical Officers

CEOs

Founders

Funders

Investors

Prescribers

Payers

Innovation Centers

Journal Editors

Health Journalists

Drug and Device Companies

Communication Companies

Health Systems

Chairs of Neurology

Executive Directors

FDA

NINDS

NIMH

NIA

ALL ARE WELCOME!

WHAT IS ASENT?

The **American Society for Experimental Neurotherapeutics (ASENT)** is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.

Register for ASENT 2023

Online Registration

In light of these unique times, the American Society for Experimental Neurotherapeutics has decided continue with our virtual format. However, in order to continue to offer an outstanding virtual conference, ASENT must charge a small fee to attend the meeting. Below you will find details on registration fees.

Meeting Rates	Member Rate	Non Member Rate
AAN Members	\$140	\$310
Academic	\$175	\$375
Advocacy	\$75	\$200
Clinician	\$175	\$375
Govt	\$175	\$225
Industry	\$325	\$575
Retired	\$75	\$200
Trainee	\$0	\$50
LMIC	\$0	\$0

TO REGISTER, VISIT: <https://asent.org/Annual-Meeting>

ASENT 2023 | SCHEDULE AT A GLANCE

MONDAY, MARCH 13, 2023

10:00am - 11:30 am	Plenary	Drug Discovery: The Last Mile in Bringing Drugs to Market	
11:30am - 11:45am	BREAK		
11:45am - 1:00pm	Concurrent Symposia	The Brain-Gut Connection in Neurodegenerative Diseases	Novel Approaches to Therapy in Epilepsy
1:00pm - 1:30pm	Sponsored Symposium		
1:30pm - 1:45pm	BREAK		
1:45pm - 3:00pm	Advances in the Molecular Pathogenesis and Therapeutics of ALS		
3:00pm - 4:00pm	Poster Presentations		
4:00pm - 5:00pm	Networking Breakout Rooms: Live Discussion with Speakers		

TUESDAY, MARCH 14, 2023

10:00am - 11:15am	Plenary	Neuro-Enabled: Next Generation Prosthetics to Restore Function	
11:15am - 11:30am	BREAK		
11:30am - 12:45pm	Concurrent Symposia	Adding Insult to Injury: The Role of Neuroinflammation in Acute Injury to the Nervous System	Moving Novel Neurotechnologies Across the Valley of Death
12:45pm - 1:00pm	BREAK		
1:00pm - 3:00pm	Pipeline Presentations		
3:00pm - 4:00pm	Poster Presentations		
4:00pm - 5:00pm	Networking Breakout Rooms: Live Discussion with Speakers		



ASENT 2023 | SCHEDULE AT A GLANCE

WEDNESDAY			
10:00am - 11:15am	Plenary	Opportunities and Obstacles for Innovators Entering the Field of Neurotherapeutics	
11:15am - 11:30am	BREAK		
11:30am - 12:45pm	Concurrent Symposia	Emerging Targets and Novel Approaches in Parkinson's Disease	Discovery and Development of Psychedelics for Neuropsychiatric Disorders
12:45pm - 1:00pm	BREAK		
1:00pm - 3:00pm	Pipeline Presentations		
3:00pm - 4:00pm	Networking Breakout Rooms: Live Discussion with Speakers		

ASENT 2023 | PROGRAM DETAIL

DAY 1: MONDAY, March 13, 2023

10:00 a.m. – 10:05 a.m.	Conference Welcome Jessica Smith <i>Executive Director</i>
10:05 a.m. – 10:10 a.m.	Presidential Opening Thomas P. Sutula, MD, PhD, University of Wisconsin, Madison <i>President</i> Andrew J. Cole, MD, Massachusetts General Hospital/Harvard <i>Incoming President</i>
10:10 a.m. – 11:30 a.m.	Presidential Symposium: Drug Discovery: The Last Mile in Bringing Drugs to Market <i>Presented in partnership with the American Academy of Neurology's Experimental Neurotherapeutics Section.</i> Chair: Samuel A. Frank, MD, FAAN, FANA, Beth Israel Deaconess Medical Center Co-Chair: Lauren Reoma, MD, National Institute of Neurological Disorders and Stroke The majority of trial work embarked on by the neurologist and the bulk of industry funded trials are in the phase 2 and phase 3 design space. Often, the development process and resources are focused on earlier stage innovations and design, leading up to the pilot, first-in-human and early phase trials. Beyond initial innovations, building the “last mile” to the pivotal registration trial is key to bringing drugs to market. Important trial methodology structures, innovation in digital designs, and necessary understanding of regulatory safety concerns ensure that early innovation in the drug and device space result in market approvals for our patients. <u>FACULTY</u> Successes and Challenges Getting Gene Therapy to Registration Thomas Crawford, MD, Johns Hopkins Medicine Accelerated Approval Pathways and the Condition of Conditional Approval: Secrets to Success Teresa Buracchio, MD, CDER, FDA Health Maximization with Neurologic Therapeutics Through Fair Pricing and Fair Access David Rind, MD, MSc, Institute for Clinical and Economic Review (ICER) PANEL DISCUSSION (LIVE)
11:30 a.m. – 11:45 a.m.	BREAK

ASENT 2023 | PROGRAM DETAIL

DAY 1: MONDAY, March 13, 2023 (Cont.)

11:45 a.m. - 1:00 p.m.	Concurrent Symposium 1	Concurrent Symposium 2
	<p>The Brain-Gut Connection in Neurodegenerative Diseases</p> <p>Chair: Suhayl Dhib-Jalbut, MD, Rutgers University Medical School Co-Chair: Sharon Tamir, Karyopharm</p> <p>The gut microbiome is believed to play an important role in neurodevelopment, autoimmune, neurodegenerative, and behavioral disorders. Gut dysbiosis, characterized by alterations in intestinal microbial composition and function, is commonly observed in Multiple Sclerosis, Parkinson's disease, Alzheimer's disease and ALS. Experimental evidence indicate that gut dysbiosis dysregulates homeostasis of the immune system and its interaction of the latter with the central nervous system. It is believed that diet is one of the most important factors affecting gut microbiota. This symposium will address the influence of the gut microbiome on neurodevelopment, pathogenesis of neurodegenerative disorders, and potential for therapeutic intervention.</p> <p><u>FACULTY</u></p> <p>Overview of the CNS and the Gut Microbiome Sarkis Mazmanian, PhD, CalTech</p> <p>The Gut Microbiome and MS Sergio E Baranzini, Ph.D., University of California San Francisco</p> <p>Targeting the Microbiome With Dietary Fiber Liping Zhao, PhD, Rutgers University Medical School</p> <p>PANEL DISCUSSION (LIVE)</p>	<p>Novel Approaches to Therapy in Epilepsy</p> <p>Chair: Aditya Joshi, MD, University of Pennsylvania Co-Chair: Amir Tamiz, PhD, NINDS</p> <p>The treatment of epilepsy remains a vexing problem in spite of an ever-expanding armamentarium of anti-seizure drugs. This symposium will examine some of the work that is being done to accelerate the development of novel treatments for epilepsy.</p> <p><u>FACULTY</u></p> <p>Karen Wilcox, PhD, NINDS Epilepsy Therapy Screening Program</p> <p>Lisa Shafer, PhD, Cerebral Therapeutics</p> <p>Ellen Bublick, MD, FAES, Brigham Health, Brigham and Women's Hospital</p> <p>PANEL DISCUSSION (LIVE)</p>
1:00 p.m. – 1:30 p.m.	Sponsored Symposium	

ASENT 2023 | PROGRAM DETAIL

DAY 1: MONDAY, March 13, 2023 (Cont.)

1:30 p.m. – 1:45 p.m.	BREAK
1:45 p.m. – 3:00 p.m.	<p>Symposium: Advances in the Molecular Pathogenesis and Therapeutics of ALS Chair: Maral Mouradian, MD, Rutgers University Medical School</p> <p>Latest advances in elucidating the molecular pathogenesis of ALS and novel therapeutic strategies.</p> <p>FACULTY</p> <p>ALS Outcomes and Clinical Trial Design Merit Cudkowicz, MD, MSC, Mass General Hospital</p> <p>Nuclear Pore Dysfunction in ALS and Neurodegeneration Jeffrey D. Rothstein, MD, PhD, Johns Hopkins University</p> <p>Title TBD Robert H. Brown MD, DPhil, University of Massachusetts</p> <p>PANEL DISCUSSION (LIVE)</p>
3:00 p.m. - 4:00 p.m.	<p>Poster Panel Discussion 1</p> <p>Chair: Carolyn Tallon, PhD, Johns Hopkins Drug Discovery</p> <p>Posters selected to be featured in the Poster Panel Discussion are chosen via the abstract submission process. ASENT welcomes encore abstracts that are relevant to the field of Neurotherapeutics. During this live poster discussion poster presenters will have 5 minutes to present their poster to a live audience and 3 minutes of Q&A for each poster presenter. This will limit our panel to 6 presentations. As such we will be looking for the highest ranked abstract submissions.</p>
4:00 p.m. - 5:00 p.m.	<p>Live Networking Rooms Discover our interactive breakout rooms where you can connect live with our leading faculty from our Day 1 sessions. You will have the opportunity to ask questions and get more in depth on the topics that matter to you.</p> <p>Day 1 Breakout Rooms</p> <ul style="list-style-type: none"> • Drug Discovery • Neurodegenerative Disease • Epilepsy • ALS <p>Select your preferred breakout room during registration. But remember you can always move between rooms.</p>

ASENT 2023 | PROGRAM DETAIL

DAY 2: TUESDAY, March 14, 2023

10:00 a.m. – 11:15 a.m.

Symposium: **Neuro-Enabled: Next Generation Prosthetics To Restore Function**

Presented in partnership with the Japanese Society of Neurological Therapeutics

This society was established in 1983 with the aim of contributing toward the therapeutic progress in the field of neurology and for a decade ASENT and JSNT have welcomed speakers at each society's respective annual meetings.

Chair: Kazuo Fujihara, MD, Fukushima Medical University School of Medicine

Co-Chair: Aditya Joshi, MD, University of Pennsylvania

Neurological disorders that impair patients' abilities to interact with the world can have a devastating impact on their quality of life. Devices that act as interfaces between the brain and an "effector" can go a long way toward helping patients return to a more normal life. In this session, we present four exciting technologies which have the potential to "neuro-enable" patients to restore some of their lost function.

FACULTY

HAL (hybrid assisted limb)

Yoshihiro Yasunaga, Cyberdyne

Visual Prostheses

Shelley Fried, PhD, Harvard Medical School, MGH

Closed Loop Brain-Computer Interfaces

Eric C. Leuthardt, MD, Washington University, St. Louis

Neural Prosthetics Project

Professor Yukio Nishimura, Tokyo Metropolitan Institute of Medical Science

PANEL DISCUSSION (LIVE)

11:15 a.m. – 11:30 a.m.

BREAK

ASENT 2023 | PROGRAM DETAIL

DAY 2: TUESDAY, March 14, 2023

11:30 a.m. – 12:45 p.m.	Concurrent Symposium 3	Concurrent Symposium 4
	<p>Adding Insult to Injury: The Role of Neuroinflammation in Acute Injury to the Nervous System</p> <p>Chair: Sharon Tamir, Karyopharm Co-Chair: Aditya Joshi, MD, University of Pennsylvania</p> <p>There is emerging evidence that neuroinflammation may both mar and mend the nervous system after an acute injury (traumatic brain injury, traumatic spine injury, and acute stroke). In this symposium, we explore some of the newest data on how inflammation may be harnessed to repair the brain and spinal cord, while minimizing additional damage.</p> <p><u>FACULTY</u></p> <p>Neuroinflammation in Traumatic Brain Injury David J. Loane, Ph.D., Trinity College, University of Dublin</p> <p>Neuroinflammation After Acute Stroke Renee Turner, PhD, University of Adelaide, Australia</p> <p>Inflammation in Acute Spinal Cord Injury Phillip Popovich, PhD, Ohio State University</p> <p>PANEL DISCUSSION (LIVE)</p>	<p>Moving novel neurotechnologies across the valley of death</p> <p>Chair: Ludy Shih, MD, MMSc, Boston University Medical School Co-Chair: Steve Schachter, MD, Beth Israel Deaconess Medical Center/Harvard</p> <p>Next generation neurotherapeutic devices are being developed to record, stimulate or block neural signaling and affect specific molecular or neurophysiologic mechanisms across a broad variety of neurologic conditions, including pain, epilepsy, movement disorders, stroke/brain injury, as well as neurodegenerative disorders. This session will cover perspectives and initiatives focused on preclinical and clinical development, as well as regulatory science development tools for new device developers hoping to bring new therapies to market.</p> <p><u>FACULTY</u></p> <p>Bioelectronic Medicines: At an Inflection Point in an Exponential Growth Curve? Kip Ludwig, PhD, University of Wisconsin</p> <p>TITLE TBD Kate Rosenbluth, PhD, Cala Health</p> <p>Introduction to OSEL and Neurological Regulatory Science Tool Development activities Dr. Zane Arp, FDA</p> <p>PANEL DISCUSSION (LIVE)</p>
12:45 p.m. – 1:00 p.m.	BREAK	

ASENT 2023 | PROGRAM DETAIL

DAY 2: TUESDAY, March 14, 2023

1:00 p.m. – 3:00 p.m.

PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline

Chair: C. Anthony Altar, PhD, Splice Therapeutic

Historically the ASENT Pipeline Presentations have been an important feature of the ASENT Annual Meeting. And now that the meeting is virtual our presenters benefit from an audience at least 3x the size of our last in person meeting.

Submitted abstracts may be selected for a 10-minute oral presentation at one of our Pipeline Presentation sessions. ASENT encourages abstracts from private, public and startup companies and government or academic labs that contain neurotherapeutic research results.

The ASENT Annual Meeting attracts leaders in neurotherapeutics from all over the world, in all neurologic disease states. Pipeline presentations increase exposure to strategic partners in life sciences who have supported novel approaches through partnerships or strategic investments.

Past presenters have reported the following results:

- Sharp increases in stock values in the days following the presentation
- Financially beneficial partnerships as a result of presentation
- Developed new companies as a result of participation in meeting

3:00 p.m. - 4:00 p.m.

Poster Panel Discussion 2

Chair: Carolyn Tallon, PhD, Johns Hopkins Drug Discovery

Posters selected to be featured in the Poster Panel Discussion are chosen via the abstract submission process. ASENT welcomes encore abstracts that are relevant to the field of Neurotherapeutics. During this live poster discussion poster presenters will have 5 minutes to present their poster to a live audience and 3 minutes of Q&A for each poster presenter. This will limit our panel to 6 presentations. As such we will be looking for the highest ranked abstract submissions.

4:00 p.m. - 5:00 p.m.

Live Networking Rooms

Discover our interactive breakout rooms where you can connect live with our leading faculty from our Day 2 sessions. You will have the opportunity to ask questions and get more in depth on the topics that matter to you.

Day 2 Breakout Rooms

- Neuroinflammation in Acute Injury
- Devices in Neurotherapeutics
- Pipeline

Select your preferred breakout room during registration. But remember, you can always move between rooms.

ASENT 2023 | PROGRAM DETAIL

DAY 3: WEDNESDAY, March 15, 2023

10:00 a.m. – 11:15 a.m.

Symposium: **Opportunities and Obstacles for Innovators Entering the Field of Neurotherapeutics**

Chair: Dietrich Haubenberger, MD, MHSc, Neurocrine Biosciences
Co-Chair: Ludy Shih, MD, MMSc, Boston University School of Medicine

There are growing opportunities for early career clinician-investigators to contemplate planning a career in the development and testing of novel neurotherapeutics, whether in the academic, government or industry setting. The goal of this session is to introduce trainees and early career faculty to skills needs assessment and training opportunities that may address the specific training needs required for this type of career.

FACULTY

TBD

Laurie Gutmann, MD, Indiana University School of Medicine

Lauren Reoma, MD, Clinical Trials Unit, NINDS

PANEL DISCUSSION (LIVE)

11:15 a.m. – 11:30 a.m.

BREAK

ASENT 2023 | PROGRAM DETAIL

DAY 3: WEDNESDAY, March 15, 2023

11:30 a.m. – 12:45 p.m.	<p>Concurrent Symposium 5</p> <p>Emerging targets and novel approaches in Parkinson’s Disease</p> <p>Chair: Debra Ehrlich, MD, NINDS Co-Chair: Amir Tamiz, PhD, NINDS</p> <p>This session will bring perspectives from industry and academia to discuss novel approaches for therapeutics development in Parkinson’s disease.</p> <p><u>FACULTY</u></p> <p>Warren D. Hirst, PhD, Biogen</p> <p>David Standaert, University of Alabama at Birmingham</p> <p>Malú Tansey, University of Florida</p> <p>PANEL DISCUSSION (LIVE)</p>	<p>Concurrent Symposium 6</p> <p>Discovery and Development of Psychedelics for Neuropsychiatric Disorders</p> <p>Chairs: Gail Farfel, PhD, ProMIS Co-Chair: Carolyn Tallon, PhD, Johns Hopkins University</p> <p>Neuropsychiatric disorders have been notoriously difficult to develop effective and well tolerated therapeutics. This session will cover the recent advancements in the use of psilocybin to treat neuropsychiatric disorders and explore the exciting new doors being opened for developing psychedelics for therapeutic use.</p> <p><u>FACULTY</u></p> <p>Joshua Woolley, MD, PhD, UCSF</p> <p>Rob Silva, Ph.D., MindMed</p> <p>Nathan Bryson, PhD, Reunion Med</p> <p>PANEL DISCUSSION (LIVE)</p>
12:45 p.m. – 1:00 p.m.	Break	
1:00 p.m. – 3:00 p.m.	<p>PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline</p> <p>Chair: C. Anthony Altar, PhD, Splice Therapeutics</p> <p>Submitted abstracts may be selected for a 10-minute oral presentation at one of our Pipeline Presentation sessions. ASENT encourages abstracts from private, public and startup companies and government or academic labs that contain neurotherapeutic research results.</p>	
3:00 p.m. - 4:00 p.m.	<p>Live Networking Rooms</p> <p>Discover our interactive breakout rooms where you can connect live with our leading faculty from our Day 3 sessions. You will have the opportunity to ask questions and get more in depth on the topics that matter to you.</p> <p><u>Day 3 Breakout Rooms</u></p> <ul style="list-style-type: none"> • Parkinson’s Disease • Psychedelics • Careers in Neurotherapeutics • Pipeline 	

ASENT Leadership

PROGRAM COMMITTEE

CHAIRS

Sharon Tamir

Karyopharm

Dietrich Haubenberger, MD, MHSc

Neurocrine Biosciences

COMMITTEE MEMBERS

C Anthony Altar, PhD

Splice Therapeutics

Enrique Carrazana, MD

Marinus Pharmaceuticals

Suhayl Dhib-Jalbut, MD

Rutgers-Robert Wood Johnson Medical School

Debra Ehrlich, MD, MS

NINDS

Gail Farfel, PhD

ProMIS

Samuel A. Frank, MD, FAAN, FANA

Beth Israel Deaconess Medical Center

Aditya Joshi, MD

University of Pennsylvania

Nancy Santilli, MSN

Human Care Systems

Carolyn Tallon, PhD

Johns Hopkins University

Danilo Vitorovic, MD

Loma Linda University

Lauren Reoma, MD

NINDS

Ludy Shih, MD, MMSc

Boston University Medical School

EX-OFFICIO PROGRAM COMMITTEE MEMBERS

Thomas P. Sutula, MD, PhD

University of Wisconsin, Madison

Andrew J. Cole, MD

Massachusetts General Hospital/Harvard

Bennett Lavenstein, MD

Children's National Health System

Amir Tamiz, PhD

NINDS

BOARD OF DIRECTORS

EXECUTIVE COMMITTEE

Thomas P. Sutula, MD, PhD, PRESIDENT

University of Wisconsin, Madison

Andrew J. Cole, MD, INCOMING PRESIDENT

Massachusetts General Hospital/Harvard

COMMITTEE MEMBERS

C Anthony Altar, PhD,

Splice Therapeutics

Enrique Carrazana, MD

Marinus Pharmaceuticals

Amy Chappell, MD

Eliam

Stewart A. Factor, DO

Emory University School of Medicine

Gail Farfel, PhD

ProMIS

Dietrich Haubenberger, MD, MHSc

Neurocrine Biosciences

Aditya Joshi, MD

University of Pennsylvania

Bennett L. Lavenstein, MD

Children's Hospital Medical Center

David Shoup

Curry Rockefeller Group

Kenneth Sommerville, MD

Sommerville Consulting

Sharon Tamir

Karyopharm

Danilo Vitorovic, MD

Loma Linda University

EX-OFFICIO BOARD

Amir Tamiz, PhD

NINDS

M. Maral Mouradian, MD

Rutgers University



REGISTRATION DETAILS

ABSTRACT SUBMISSIONS

<https://bit.ly/abstractsasant2023>

Abstract Submission Deadline: January 23, 2023

ANNUAL MEETING REGISTRATION

<https://asant.org/Annual-Meeting>

Annual Meeting Registration Deadline: March 13, 2023

Contact us at **caroline@asant.org** for additional information.